教員業績データベース   
   English >>
  1. TOPページ
    2. >
  2. 臨床医学系講座
    3. >
  3. 呼吸器・血液内科学

学術論文
著書
学会発表
    （最終更新日：2022-06-21 11:04:43）
  イケガメ カズヒロ   Ikegame Kazuhiro
  池亀 和博
   所属   （専門部門）  臨床医学系講座 呼吸器・血液内科学
   職種   講師
■ 学術論文
1. 原著　 Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospectiv phaseⅠ/Ⅱ study 2020/06
2. 原著　 Effects of Antifungal Stewardship Using Therapeutic Drug Monitoring in Voriconazole Therapy on the Prevention and Control of Hepatotoxicity and Visual Symptoms: A Multicentre Study Conducted in Japan. 2020/08
3. その他　 Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3); comparison with normal karyotype. 2020/07
4. 原著　 Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Myeloid Leukemia Conducted in Japan During the Past Quarter Century. 2020/06
5. 総説　 Clinical practice recommendations for the diagnosis and management of human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation: the Japan Society for Hematopoietic Cell Transplantation. 2020/06
6. 原著　 Mixed Chimerism and Secondary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. 2020/03
7. 原著　 Antigen-presenting cells constitutively bind tumor antigens in the tumor-bearing state in vivo to construct an effective immunogenic unit. 1991/03
8. 原著　 Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts. 1991/03
9. 原著　 Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity. 1992/01
10. 原著　 Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells. 1992/01
11. 原著　 Cloning and functional analysis of new members of STAT induced STAT inhibitor (SSI) family: SSI-2 and SSI-3. 1997/08
12. 原著　 A new member of a hepatoma-derived growth factor gene family can translocate to the nucleus. 1999/12
13. 症例報告　 Pleural effusion during interferon treatment for chronic hepatitis C. 2000/09
14. 症例報告　 Lethal adenovirus infection in a patient who had undergone nonmyeloablative stem cell transplantation. 2001/07
15. その他　 Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. 2002/07
16. その他　 Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. 2002/07
17. その他　 Antibodies against hepatoma-derived growth factor and mucosal repair in ulcerative colitis. 2002/11
18. 症例報告　 Successful treatment of refractory T-cell acute lymphoblastic leukemia by unmanipulated stem cell transplantation from an HLA 3-loci mismatched (haploidentical) sibling. 2003/03
19. その他　 The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. 2003/03
20. その他　 Treatment of severe life-threatening graft-versus-host disease by autologous peripheral blood stem cell transplantation using a nonmyeloablative preconditioning regimen. 2003/03
21. その他　 The effect on the proliferation and apoptosis of alloreactive T cells of cell dose in a murine MHC-mismatched hematopoietic cell transplantation model. 2003/04
22. 症例報告　 Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin. 2003/06
23. その他　 Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer. 2003/07
24. その他　 Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. 2003/07
25. 原著　 Successful engraftment of HLA-haploidentical related transplants using nonmyeloablative conditioning with fludarabine, busulfan and anti-T-lymphocyte globulin. 2003/10
26. その他　 Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). 2003/11
27. 原著　 Absence of mutations in the Wilms' tumor gene wt1 in de novo non-small cell lung cancers. 2004/01
28. その他　 Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer. 2004/02
29. その他　 Allogeneic bone marrow transplantation with non-T-cell-depleted marrow from two HLA-antigen-mismatched related donors. 2004/03
30. 原著　 Identification of a gene element essential for leukemia-specific expression of transgenes. 2004/03
31. その他　 Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. 2004/03
32. 原著　 Preferential expression of the vasoactive intestinal peptide (VIP) receptor VPAC1 in human cord blood-derived CD34+CD38- cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells. 2004/05
33. その他　 Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation. 2004/06
34. その他　 Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. 2004/07
35. その他　 WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. 2004/07
36. その他　 Powerful graft-versus-leukemia effects exerted by HLA-haploidentical grafts engrafted with a reduced-intensity regimen for relapse following myeloablative HLA-matched transplantation. 2004/08
37. その他　 Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. 2004/09
38. その他　 WT1 gene transcript assay for relapse in acute leukemia after transplantation. 2004/09
39. その他　 Successful treatment of tacrolimus (FK506)-related leukoencephalopathy with cerebral hemorrhage in a patient who underwent nonmyeloablative stem cell transplantation. 2004/10
40. その他　 Unmanipulated reduced-intensity stem cell transplantation from a haploidentical donor mismatched at 3 HLA antigens to a patient with leukemic transformation of myelodysplastic syndrome: successful second transplantation after graft rejection. 2004/12
41. 原著　 Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. 2005/02
42. 原著　 HLA-haploidentical nonmyeloablative stem cell transplantation: induction to tolerance without passing through mixed chimaerism. 2005/04
43. その他　 A case of immune recovery vitritis induced by donor leukocyte infusion for the treatment of cytomegalovirus retinitis. 2005/10
44. その他　 [HLA-haploidentical minitransplantation]. 2006/07
45. 症例報告　 Idiopathic thrombocytopenic purpura after influenza vaccination in a bone marrow transplantation recipient. 2006/08
46. その他　 Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. 2006/10
47. その他　 Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. 2008/01
48. その他　 [Chronic inflammatory demyelinating polyradiculoneuropathy and hyponatremia in a patient with chronic graft versus host disease]. 2008/06
49. その他　 Unrelated umbilical cord blood transplantation using a TBI/FLAG conditioning regimen for adults with hematologic malignancies. 2008/08
50. その他　 Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor. 2008/09
51. その他　 Hepatosplenic alphabeta T cell lymphoma. 2010/04
52. その他　 Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells. 2010/04
53. その他　 Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. 2010/09
54. その他　 Dasatinib is effective against optic nerve infiltration of Philadelphia chromosome-positive acute lymphoblastic leukemia. 2010/10
55. その他　 Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia. 2011/01
56. その他　 Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene. 2011/02
57. その他　 Direct antiglobulin test-negative autoimmune hemolytic anemia associated with HLA-haploidentical stem cell transplantation. 2011/04
58. その他　 Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan. 2011/04
59. その他　 Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation. 2011/08
60. その他　 Strategy for bone marrow transplantation in eculizumab-treated paroxysmal nocturnal hemoglobinuria. 2011/10
61. その他　 Dasatinib-induced rapid regression and complete molecular remission of multiple subcutaneous tumours presenting as relapsed chronic myeloid leukaemia after cord blood transplantation. 2011/12
62. 原著　 Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning 2012/03
63. その他　 Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation. 2012/04
64. その他　 Intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning treatment: a phase I study. 2012/04
65. 原著　 Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT 2012/04
66. 原著　 Incidence of extramedullary relapse after haploidentical SCT for advanced AML/myelodysplastic syndrome 2012/05
67. その他　 Feasibility of unmanipulated haploidentical stem cell transplantation using standard GVHD prophylaxis for HLA-homozygous patients. 2012/07
68. その他　 Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation. 2012/08
69. 原著　 Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors 2012/10
70. その他　 Haploidentical hematopoietic stem cell transplantation for lymphoma with monosomy of chromosome 6 (loss of heterozygosity in the HLA region)--who should be a donor? 2012/12
71. その他　 Impact of the mobilization regimen and the harvesting technique on the granulocyte yield in healthy donors for granulocyte transfusion therapy. 2012/12
72. その他　 Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation. 2012/12
73. 原著　 Allogeneic hematopoietic stem cell transplantation for intermediate cytogenetic risk AML in first CR 2013/01
74. その他　 【移植片対宿主病(GVHD)の制御】 HLA不適合移植におけるGVHD制御 2013/04
75. 原著　 Gender differences in health-related quality of life, physical function and psychological status among patients in the early phase following allogeneic haematopoietic stem cell transplantation. 2013/05
76. 原著　 Safety and feasibility of physical therapy in cytopenic patients during allogeneic haematopoietic stem cell transplantation. 2013/05
77. 原著　 Frequency of CD4(+)FOXP3(+) regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. 2013/06
78. 原著　 Impact of hepatitis C virus infection on clinical outcome in recipients after allogeneic hematopoietic cell transplantation. 2013/06
79. 原著　 Impact of a donor source on adult Philadelphia chromosome-negative acute lymphoblastic leukemia: a retrospective analysis from the Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. 2013/07
80. 原著　 Relationship between corticosteroid dose and declines in physical function among allogeneic hematopoietic stem cell transplantation patients. 2013/08
81. 原著　 Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: possible association with nelarabine. 2013/10
82. 総説　 血縁HLA不適合移植におけるGVHD制御の現状と展望 2013/10
83. 原著　 Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. 2013/11
84. 原著　 Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease 2014/02
85. 総説　 【造血幹細胞移植の合併症とその管理】 臍帯血移植後大腸炎症候群におけるBradyrhizobium entericaの発見物語 2014/03
86. 総説　 臍帯血移植後大腸炎症候群におけるBradyrhizobium enteriaの発見物語 2014/03
87. 原著　 Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning. 2014/04
88. 原著　 Risk analysis of falls in patients undergoing allogeneic hematopoietic stem cell transplantation. 2014/08
89. 原著　 Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT 2014/09
90. 総説　 難治性造血器・固形腫瘍の新たな治療戦略 血縁HLA半合致移植(ハプロ移植)の現状とこれから 2014/12
91. 原著　 [Current and future status of haploidentical hematopoietic stem cell transplantation]. 2015/03
92. 総説　 【血液分野の最新情報2015-バイオロジーを中心に(造血幹細胞移植)-】 血縁HLA半合致移植(ハプロ移植)の現状と今後 2015/03
93. 原著　 Prediction of Skin Trouble in Patients Undergoing Allogeneic Hematopietic Stem Cell transplantation Using Generalized Additive Model. 2015/04
94. 原著　 Pharmacokinetics of 8 mg/kg anti-human T-lymphocyte rabbit immunoglobulin conditioning for hematopoietic stem cell transplantation in Japanese patients. 2015/05
95. 原著　 日本人における造血幹細胞移植前処置時の抗ヒトTリンパ球ウサギ免疫グロブリン8mg/kg投与時の薬物動態 2015/05
96. その他　 A single high-resolution HLA mismatch has a similar adverse impact on the outcome of related hematopoietic stem cell transplantation as a single low-resolution HLA mismatch. 2015/07
97. 原著　 Unmanipulated HaploidenticalReduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Study in Japan. 2015/08
98. 原著　 Balance function in patients who had undergone allogeneic hematopoietic stem cell transplantation. 2015/09
99. 原著　 Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation. 2015/10
100. その他　 Early-phase differences in health-related quality of life, psychological status, and physical function between human leucocyte antigen-haploidentical and other allogeneic haematopoietic stem cell transplantation recipients. 2015/10
101. 総説　 高齢者による貧血の特徴と鑑別 2015/10
102. 原著　 Host Foxp3+CD4+ Regulatory T Cells Act as a Negative regulator of dendritic cells in the peritransplantation period. Journal of Immunology. 2016/01
103. 症例報告　 Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity. 2016/02
104. 原著　 急性リンパ性白血病幹細胞移植後に腹腔内デスモイド腫瘍を認めた1例 2016/10
105. 原著　 Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes. 2016/11
106. 総説　 【白血病学(下)-最新の基礎、臨床研究-】 白血病治療の副作用・合併症対策と支持療法　造血幹細胞移植の副作用と対策　生着症候群と移植後血球貪食症候群 2016/12
107. 総説　 感染対策Expert Lecture　同種造血幹細胞移植に伴う高度免疫不全患者における抗菌薬・抗真菌薬・抗ウイルス薬による感染症治療のポイント 2016/12
108. 総説　 同種造血幹細胞移植に伴う高度免疫不全患者における抗菌薬・抗真菌薬・抗ウイルス薬による感染症治療のポイント 2016/12
109. 原著　 Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHC 2017/02
110. 症例報告　 Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation 2017/05
111. 原著　 Spousal hematopoietic stem cell transplantation 2017/05
112. 原著　 Relationship of physical activity with physical function and health-related quality of life in patients having undergone allogeneic haematopoietic stem-cell transplantation 2017/07
113. 原著　 Impact of the presence of HLA 1-locus mismatch and the use of low-dose antithymocyte globulin in unrelated bone marrow transplantation 2017/10
114. 総説　 【HLA半合致移植の現状】 各種薬剤を用いたHLA半合致移植　ATG(anti-thymocyte globulin)HLA半合致移植 2017/11
115. 原著　 Fatigue, Muscle Oxygen Consumption and Blood Flow to the Skeletal Muscle After Allogeneic Hematopoietic Stem Cell Transplantation. 2018
116. その他　 Hemoglobin Dynamics in the Skeletal Muscle of Patients with Malignant Hematopoietic Disease. 2018/01
117. 原著　 A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning. 2018/04
118. 原著　 Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR. 2018/04
119. 原著　 Impaired skeletal muscle oxygenation following allogeneic hematopoietic stem cell transplantation is associate with exercise capacity 2018/07
120. 原著　 Changes in Borg scale for resistance training and test of exercise tolerance in patients undergoing allogeneic hematopoietic stem cell transplantation. 2018/09
121. 原著　 Hemoglobin Dynamics in the Skeletal Muscle of Patients with Malignant Hematopoietic Disease. 2018/09
122. 総説　 ATGを用いたHLA半合致移植 2018/11
123. 総説　 【同種造血幹細胞移植の最近の展開】 ATGを用いたHLA半合致移植 2018/11
124. 原著　 リカレントニューラルネットワークを活用したイベントヒストラリー解析 2019/02
125. 症例報告　 Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor. 2019/03
126. 原著　 HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome. 2019/05
127. その他　 HLA discrepancy between graft and host rather than that graft and first donor impact the second transplant outcome. 2019/05
128. 原著　 Low incidence of HHV-6 reactivation in haploidentical hematopoietic stem cell transplantation with corticosteroid as graft-vs-host disease prophylaxis compared with cord blood transplantation. 2019/06
129. 原著　 Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. 2019/07
130. その他　 Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation. 2019/07
131. 原著　 Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial. 2019/07
132. 原著　 Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups. 2019/08
133. 原著　 Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups. 2019/08
134. 原著　 Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantation registry. 2019/09
135. 原著　 Hematopoietic stem-cell transplantation in children with refractory acute myeloid leukemia. 2019/09
136. 原著　 Risk Stratification and Prognosticators of Acute Myeloid Leukemia with Myelodysplasia-Related Changes in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. 2019/09
137. 症例報告　 Effect of low platelet HLA-C expression on donor-specific antibody depletion following platelet transfusion from a corresponding HLA donor. 2019/10
138. 原著　 Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation. 2019/11
139. 原著　 Impact of High-Frequency HLA Haplotypes on Clinical Cytomegalovirus Reactivation in Allogeneic Hematopoietic Stem Cell Transplantation. 2019/12
140. 原著　 Relationship Between Exercise Capacity and Muscle O2 2020
141. その他　 Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease. 2020/01
142. 原著　 Hematopoietic Stem Cell Transplantation in Solid Organ Recipients with Emphasis on Transplant Complications: A Nationwide Retrospective Survey on Behalf of the Japan Society for Hematopoietic Stem Cell Transplantation Transplant Complications Working Grou 2020/01
143. 原著　 Relationship Between Exercise Capacity and Muscle O2Hb Saturation in Patients Before Hematopoietic Stem-Cell Transplantation. 2020/01
144. 原著　 Relationship Between Muscle Oxygen Saturation and Exercise Load in Patients with Malignant Hematopoietic Disease 2020/01
145. 原著　 Could the minimum number of haematopoietic stem cells to obtain engraftment exist in unrelated, single cord blood transplantation? 2020/02
146. 原著　 A consideration for efficient unrelated hematopoietic stem cell source acquisition-from an experience of Japan. 2020/03
147. 原著　 Heterogeneous Impact of Cytomegalovirus Reactivation on Nonrelapse Mortality in Hematopoietic Stem Cell Transplantation. 2020/03
148. 原著　 Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study. 2020/03
149. 原著　 フレイルティ付きリカレントニューラルネットワークを活用したイベントヒストリー解析 2020/03
150. 原著　 Relationship Between Exercise Capacity and Muscle O(2)Hb Saturation in Patients Before Hematopoietic Stem-Cell Transplantation 2020/06
151. 原著　 Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission 2020/07
152. 症例報告　 Toxoplasmic Encephalitis Followed by Primary EBV-Associated Post-Transplant Lymphoproliferative Disorder of the Central Nervous System in a Patient Undergoing Allogeneic Hematopoietic Stem Cell Transplant: A Case Report 2020/08
153. その他　 Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation. 2020/09
154. 原著　 Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with paroxysmal nocturnal hemoglobinuria 2020/09
155. 原著　 Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection. 2020/12
156. 原著　 Muscle oxygen extraction and lung function are related to exercise tolerance after allogeneic hematopoietic stem cell transplantation 2021/03
157. 原著　 Muscle oxygen extraction and lung function are related to exercise tolerance after allogeneic hematopoietic stem cell transplantation 2021/08
158. 原著　 Severe acute graft-versus-host disease increases the incidence of blood stream infection and mortality after allogeneic hematopoietic cell transplantation: Japanese transplant registry study. 2021/09
159. 原著　 Syngeneic hematopoietic stem cell transplantation for acute myeloid leukemia: a propensity score-matched analysis. 2021/09
160. 原著　 Cytomegalovirus reactivation is associated with an increased risk of late-onset invasive aspergillosis independently of grade II-IV acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation: JSTCT Transplant Complications Working Group. 2021/12
161. 原著　 Impact of HLA disparity on the risk of overall mortality in patients with grade II-IV acute GVHD on behalf of the HLA Working Group of Japan Society for Hematopoietic Cell Transplantation. 2021/12
162. 原著　 Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. 2022/01
163. 原著　 Deletion of Y-chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors. 2022/02
164. 原著　 Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia. 2022/03
165. 原著　 HLA 1-3 antigen-mismatched related peripheral blood stem cells transplantation using low-dose antithymocyte globulin versus unrelated cord blood transplantation. 2022/03
166. 原著　 Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group. 2022/04
167. 原著　 Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. 2022/04
5件表示
全件表示(167件)
■ 著書
1. 分担執筆　 HLA不適語合移植後再発に対するリンパ球輸注療法は安全に実施できるか？「EBM血液疾患の治療2015－2016」 2014/10
2. 分担執筆　 顆粒球輸血の感染症の予後への影響「EBM血液疾患の治療2017－2018」 2016/10
3. 分担執筆　 HLA半合致移植（PTCY以外）「血液疾患最新の治療2017－2019」 2017/02
4. 編集・監修　 日本造血細胞移植学会　造血細胞移植ガイドライン　HLA不適合血縁者間移植（第２版）「日本造血細胞移植学会　造血細胞移植ガイドライン　HLA不適合血縁者間移植（第２版）」 2018/09
■ 学会発表
1. high risk悪性血液疾患患者に対する，低容量ATGとステロイドを用いたHLA半合致ミニ移植の治療成績 （ポスター，一般） 2013/03/01
2. ABO副不適合造血幹細胞移植におけるドナー由来抗赤血球抗体賛成の検討 （ポスター，一般） 2013/03/08
3. 血縁HLA半合致ミニ移植（haplo-mini)の他施設前向き臨床試験（第Ⅰ/Ⅱ相試験） （口頭発表，一般） 2013/03/08
4. 同種造血幹細胞移植患者のステロイド投与量と身体機能低下の関連性について （ポスター，一般） 2013/03/08
5. 移植後Hemophagocytic Syndromeを合併したAMLの1例 （ポスター，一般） 2013/03/09
6. Higher corticosteroid dose declines physical function, but does not affect psychosocial function among allogeneic hematopoietic stem-cell transplantation patients （ポスター，一般） 2013/06
7. HLA半合致移植におけるCOnditioning．（一般口演） （口頭発表，一般） 2013/07/27
8. Effect of physical therapy on physical function and QOL in patients undergoing allogeneic hematopoietic transplantation （ポスター，一般） 2013/09
9. CMV colitis and chronic activated state in a CML patient during treatment with dasatinib. （口頭発表，一般） 2013/10/11
10. Transition of conditioning regimen in haplo-mini in connection with surcical results.（一般口演） （口頭発表，一般） 2013/10/13
11. HLA haploidentical transplantation and further. （口頭発表，特別・招待講演等） 2013/11/03
12. ATLに対する抗CCR4抗体治療の免疫学的問題 （口頭発表，一般） 2013/11/09
13. 難治性造血器・固形腫瘍の新たな治療戦略 血縁HLA半合致移植(ハプロ移植)の現状とこれから（シンポジウム） （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2013/12/01
14. 同種造血幹細胞移植患者の臀部・陰部皮膚トラブル発生要因解析．（一般口演） （口頭発表，一般） 2014/03/07
15. 顆粒球採取ドナーの採取に伴う副作用と採取後健康調査 （ポスター，一般） 2014/03/07
16. HLA半合致ドナーと他のドナーによる造血幹細胞移植患者の健康関連QOL，精神機能，身体機能の違いについて （ポスター，一般） 2014/03/08
17. Rituximabが著効した臍帯血移植後晩期発症のPRCA （ポスター，一般） 2014/03/08
18. ハプロ移植コーディネートの困難性．（ポスター発表） （ポスター，一般） 2014/03/08
19. 血縁者間同種移植においてGVH方向のallele不適合はGVHDのリスク因子となる．（一般口演） （口頭発表，一般） 2014/03/08
20. 造血幹細胞移植における合併症マネジメント―臨床現場での取り組み―．（アフタヌーンティーセミナー） （口頭発表，特別・招待講演等） 2014/03/08
21. 造血幹細胞移植後再発低悪性度リンパ腫に対するゼヴァリン治療の有用性と安全性 （口頭発表，一般） 2014/03/09
22. haploidentical transplantation and further （口頭発表，一般） 2014/04
23. Early-phase differences in health-related QOL, psychological status, and physical function between HLA-haploidentical and other allo-HSCT recipients （口頭発表，一般） 2014/06
24. Azacitidineが奏効したAMLの1例 （口頭発表，一般） 2014/06/28
25. 移植後再発に対する夫婦間造血幹細胞移植の1例 （口頭発表，一般） 2014/06/28
26. Graft-versus-GVHD, a second transplantation from another donor for the resucue from refractory acute GVHD. （口頭発表，一般） 2014/09
27. Analysis for HBV reactivation in CML treated with TKIs （口頭発表，一般） 2014/10
28. Morning Discussion (Meet the Expert) （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2014/10
29. Soluble interleukin-2 receptor level on day 7 asna predictor of GVHD after HLA-haploidentical RIST. （口頭発表，一般） 2014/10
30. XLAに対する同種造血幹細胞移植の1例 （口頭発表，特別・招待講演等） 2015/01/24
31. Prediction of Skin Trouble in Patients Undergoing Allogeneic Hematopietic Stem Cell transplantation Using Generalized Additive Model （口頭発表，一般） 2015/02
32. Spousal Hematopoietic Stem Cell Transplantation for Post-transplantation Relapse/Rejection. （口頭発表，一般） 2015/02
33. The Impact of HLA Mismatch Only in the Host-Versus-Graft Direction on the Outcome of Related Hematopoietic Stem Cell Transplantation for Patients with HLA-Homozygous Haplotype: A Retrospective Analysis of The JSHCT HLA Working Group Study （口頭発表，一般） 2015/02
34. “Low Incidence of Human Herpesvirus 6 Reactivation in Unmanipulated HLA-Haploidentical Related Stem Cell Transplantation with Corticosteroid As Graft-Versus-Host Disease Prophylaxis. （口頭発表，一般） 2015/02
35. 造血幹細胞移植患者における移植前と移植時の身体活動量について （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2015/03
36. 同種造血幹細胞移植の適応とドナーの選択：成人 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2015/03
37. ハプロタイプを共有しない血縁ドナーからの造血幹細胞移植  2015/03/05
38. 骨髄内骨髄移植のための骨髄液濃縮方法の確立 （ポスター，一般） 2015/03/05
39. The secondary central nervous system (CNS) lymphomaに対するhaplo-mini SCT治療の検討 （ポスター，一般） 2015/03/06
40. ハプロタイプを共有しない血縁ドナーからの造血幹細胞移植 （口頭発表，一般） 2015/03/06
41. ホモ接合型HLAハプロタイプを持つ患者の血縁者間造血幹細胞移植におけるHVG方向のみHLA不適合の影響：JSHCT　HLAワーキンググループによる後方視的解析 （口頭発表，一般） 2015/03/06
42. 樹状細胞の成熟はホスト由来制御性T細胞により抑制される：GVHD発症における重要な役割について （口頭発表，一般） 2015/03/06
43. 造血幹細胞移植患者における移植前後のバランス機能について （ポスター，一般） 2015/03/06
44. 造血幹細胞移植患者の筋力低下は移植直後の時点で起こっている （ポスター，一般） 2015/03/06
45. 無菌室内運動療法が筋酸素代謝に及ぼす影響 （ポスター，一般） 2015/03/06
46. Based on haplo, beyond haplo. （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2015/03/07
47. Spectra Optia を用いた高分子HES使用の有無による顆粒球採取効率の検討第2報―HES未使用プロトコールの検討― （ポスター，一般） 2015/05
48. Bruton型ガンマグロブリン血症に対して同種造血幹細胞移植を施行した1例 （口頭発表，一般） 2015/10
49. Clinical relevance of the monitoring of VWF activity in the management of essential thrombocythemia. （口頭発表，一般） 2015/10
50. Risk analysis of falls and skin lesions in patients undergoing allogeneic hematopoietic stem cell transplantation. （口頭発表，一般） 2016/02
51. Unmanipulated HLA haploidentical allogeneic stem cell transplantation from family members using Steroid-containing GVHD prophylaxis for refractory hematological malignancies. （口頭発表，一般） 2016/02
52. ブルトン型無ガンマグロブリン血症に対する同種造血幹細胞移植～液性免疫再構築モデルとして～ （口頭発表，一般） 2016/03/04
53. 血液悪性疾患における移植ソース別GRFSの解析：JSHCT Working Group研究 （口頭発表，一般） 2016/03/04
54. 当院におけるフィラデルフィア染色体陽性急性リンパ性白血病に対するHLA半合致同種造血幹細胞移植成績 （口頭発表，一般） 2016/03/04
55. 臍帯血移植後長期に渡り混合キメラ状態が続き、経過中溶血性貧血を合併しその後再発したMDSに対し、HLA半合致移植を施行した1例 （ポスター，一般） 2016/03/04
56. AML PIF、臓器機能や全身状態は保たれている患者に兵庫医大ハプロを選択する （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2016/03/05
57. Unmanipulated haploidentical RIST using Fludarabine, Busulfan, low-dose ATG and steroid for patients in non-CR or at high risk of relapse: a prospective multicenter phase III study in Japan.” （口頭発表，一般） 2016/05
58. 計画的にTKIを中止しINF-αでdeep molecular responseを到達、維持しながら出産したCML-CP （口頭発表） 2016/06/18
59. Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GVHD: a JSHCT analysis （口頭発表，一般） 2016/10
60. 超ハイリスク造血細胞移植における真菌感染対策～そこまでやるか編～ （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2016/11
61. ドナー特異的HLA抗体（DSA）と対応するHLA抗原を発現した血小板輸血でDSAを効果的に減弱した一例 （ポスター，一般） 2017/03/02
62. 急性GVHDによる重度肝機能障害に対し造血幹細動と同一のドナーから生体肝移植を施行した急性骨髄性白血病の1例 （ポスター，一般） 2017/03/02
63. 造血幹細胞患者の移植前における筋力増強練習時の負荷量と自覚的運動強度について （ポスター，一般） 2017/03/02
64. 同種造血幹細胞移植後に神経症状を呈し経過中に増悪した一例～トキソプラズマ症と中枢神経系EBV関連移植後リンパ増殖性疾患～ （ポスター，一般） 2017/03/02
65. 造血幹細胞移植前後における6分間歩行テストの生理学的特徴について （ポスター，一般） 2017/03/03
66. 同種造血幹細胞移植の多様な障害像に対する他職種チーム医療の実践について−理学療法士の観点から− （口頭発表，特別・招待講演等） 2017/03/03
67. HLA半合致移植における抗ヒト胸腺細胞ウサギ免疫グロブリン製剤の血中濃度モニタリングとGVHD重症度の関係性 （口頭発表，一般） 2017/03/04
68. KRd(carfilzomib、lenalidomide and dexamethasone)が奏効したplasmacytomaの1例 （口頭発表，一般） 2017/06/17
69. Relationship between muscle endurance and muscle oxidative consumption in patients who received allogeneic hematopoietic stem cell transplantation （ポスター，一般） 2017/06/27
70. Effectiveness of balance exercise assist robot (BEAR) for allogeneic hematopoietic stem cell transplantation patients: a preliminary study （ポスター，一般） 2017/06/28
71. Muscle oxygen consumption and blood flow to the skeletal muscle in patients with malignant hematopoietic disease （ポスター，一般） 2017/08/19
72. カンジダ血症における抗真菌薬使用量の多施設調査　日本医真菌学会関西支部「深在性真菌症研究会」 （口頭発表，一般） 2017/09/30
73. MDSに対する低用量AraCとAzacitidineの交代療法 （ポスター） 2017/10/20
74. 血液腫瘍患者の下肢筋力には血清ヘモグロビン値と骨格筋における酸素抽出能が関与している （ポスター，一般） 2018/02/01
75. 造血幹細胞移植患者の6分間歩行距離と筋力、生理学的反応の関連性について （ポスター，一般） 2018/02/02
76. 造血幹細胞移植患者の移植前後における筋力増強練習時の負荷量と自覚的運動強度について （ポスター，一般） 2018/02/02
77. 非寛解白血病に対するハプロミニ移植におけるWT1測定の意義：単施設解析 （口頭発表，一般） 2018/02/02
78. アデノウイルス11型抗体による出血性膀胱炎の発症予測とシドフォビル予防投与の有用性に関する検討 （口頭発表，一般） 2018/02/03
79. Muscle oxygen saturation during muscle endurance test in patients with malignant hematopoietic disease （ポスター，一般） 2018/07/03
80. Relationship between exercise capacity and muscle O2Hb saturation in patients before hematopoietic stem-cell transplantation （口頭発表，一般） 2018/07/04
81. The effect of balance exercise assist robot (BEAR) to patient after allogenetic hematopoietic stem cell transplantation (allo-HSCT); preliminally study. （ポスター，一般） 2018/07/08
82. Changes in heart rate and Borg scale after the exercise-tolerance test in allogeneic hematopoietic stem cell transplantation patients （ポスター，一般） 2018/07/11
83. Duration of remission with autologous hematopoietic recovery after CBT in leukemia. （ポスター，一般） 2018/10
84. The alternating therapy of azacitidine and Ara-C may improve survival of AML/MDS （口頭発表，一般） 2018/10
85. A case of the hemophagocytic syndrome with a Guillain-Barre syandorome-like symptom after delivery
分娩後にギランバレー症候群様症状で発症した血球貪食症候群の一例 （ポスター，一般） 2018/10/12
86. Prognostic models after stem cell transplantation using deep learning and general additive model. （口頭発表，一般） 2018/10/12
87. The efficacy of mesenchymal stem cells for treatment of steroid-refractory acute GVHD. （口頭発表，一般） 2018/10/13
88. Detailed bone marrow plasma cell phenotyping in the patients with suspected plasma cell disorders. （口頭発表，一般） 2018/10/14
89. Allogeneic stem cell transplantation in acute myeloid leukemia with myelodysplasia-related changes （口頭発表，一般） 2019/03
90. ドナー特異的HLA-C抗体に対して同抗原を発現した血小板輸注を行うも抗体価を減弱できなかった一例 （ポスター，一般） 2019/03
91. 日本人同種造血幹細胞移植患者における抗ヒト胸腺細胞ウサギ免疫グロブリンの血中動態とその変動要因の検討 （口頭発表，一般） 2019/03
92. ABO副不適合末梢血幹細胞移植後のドナー由来赤血球抗体産生 （口頭発表，一般） 2019/03/08
93. AYA世代におけるHLA半合致移植－移植の成績と問題点－ （口頭発表，一般） 2019/03/08
94. HLA-mismatched stem cell transplantation from family member for super-high risk disease. （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2019/03/08
95. HLA-mismatched stem cell transplantation from family members for super-high risk disease （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2019/03/08
96. homeostatic proliferationを介して、steroid抵抗性に増殖する骨髄ドナーT細胞は、GVHとGVLの乖離を起こす （口頭発表，一般） 2019/03/08
97. SpectraOptiaによる顆粒球採取125件におけるHES使用・非使用群の後方視的解析 （口頭発表，一般） 2019/03/08
98. 兵庫医大式ハプロミニ移植でもCMV再活性化はAML再発リスクを減少させるか？ （口頭発表，一般） 2019/03/08
99. 末梢血幹細胞採取における採取前HPC測定の有用性の検討 （ポスター，一般） 2019/03/08
100. 移植実績に基づく同種造血幹細胞移植細胞ソースの入手に関する検証 （口頭発表，一般） 2019/03/09
101. 当科における同種造血幹細胞移植後の2次性悪性腫瘍 （口頭発表，一般） 2019/03/09
102. 発作性夜間ヘモグロビン尿症に対する同種造血幹細胞移植の後方視的解析 （口頭発表，一般） 2019/03/09
103. Spectra Optiaによる顆粒球採取の運用と後方視的解析 （口頭発表，一般） 2019/05/25
104. 同種末梢血幹細胞移植における血液型副不適合およびドナー由来赤血球抗体産生の臨床的意義 （口頭発表，一般） 2019/05/25
105. Impaired muscle oxygen consumption during exercise after allo-HSCT is related to lower muscle mass at the time of engraftment in a sterile isolation room （ポスター，一般） 2019/06/11
106. The effect of Balance Exercise Assist Robot (BEAR) is related to balance function before intervention in patients after allogeneic hematopoetic stem cell transplantation. （ポスター，一般） 2019/06/11
107. Ph陽性ALL患者における移植後TKI維持療法の有用性 （口頭発表，一般） 2019/10
108. ボリコナゾール投与中の患者においてレテルモビルがタクロリムスの血中濃度に及ぼす影響についての解析 （ポスター，一般） 2019/11/03
109. ATL様のflower cellを呈した治療抵抗性T細胞腫瘍に対して造血幹細胞移植を行ったHIV感染症の一例 （ポスター，一般） 2019/11/28
110. The Optimal Treatment Strategy for Adult Patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia in First Remission in the Era of High-intensity Chemotherapy. （口頭発表，一般） 2019/12
111. Phase II trial of fecal microbiota transplantation for steroid-resistant gastrointestinal acute GVHD （口頭発表，一般） 2020/03
112. 日本人造血幹細胞移植患者におけるcidofovirの血中動態 （口頭発表，一般） 2020/03
113. HLA半合致幹細胞移植後寛解期に抗NMDA受容体脳炎を発症した血液腫瘍例 （口頭発表，一般） 2020/03/06
114. 同種移植後生着不全に対する救援再移植における血縁班合致ドナーと臍帯血の比較 （口頭発表，一般） 2020/03/06
115. 日本人造血幹細胞移植患者におけるcidofovirの血中動態 （口頭発表，一般） 2020/03/06
116. t(1;19)(q23;p13.3)を伴う成人急性リンパ性白血病に対する同種移植の成績 （口頭発表，一般） 2020/03/07
117. レテルモビルがボリコナゾールの血中濃度に及ぼす影響 （ポスター，一般） 2020/03/07
118. 高リスク疾患に対する、少量ATGとステロイドを用いた未処理HLA半合致造血細胞移植 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2020/03/07
119. 自家末梢血幹細胞移植後に急性GVHDを発症したDLBCLの1例 （ポスター，一般） 2020/03/07
120. 髄外性骨髄腫瘤を伴ったAMLに対する同種造血幹細胞移植に関する後方視的解析 （口頭発表，一般） 2020/03/07
121. 非寛解期AMLに対する低用量ATGとsteroidを用いる兵庫医大型haplo移植の成績-HLA適合同胞間移植との比較 （口頭発表，一般） 2020/03/07
122. 移植後再発に対する、両方のHLAがともに異なる血縁ドナーからの移植（フルアロ移植） （一般） 2020/05
123. Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukaemia with high hyperdiploidy: A retrospective nationwide study of the Japan Society for Hematopoietic Cell Transplantation （口頭発表，一般） 2020/06
124. 兵庫医科大学病院における女児及びAYA世代の女性の血液, がん患者に対する妊孕性温存 （一般） 2020/11
125. ハプロ移植、フルアロ移植後のAYA世代血液腫瘍患者における意思決定 （一般） 2021/03
126. リカレントニューラルネットワークを用いた移植後生存時間解析 （一般） 2021/03
127. 当院における再発・難治性DLBCLに対するCAR-T細胞治療の経験 （一般） 2021/03
128. (タイトル和訳中)偶発的に見出された形質細胞性腫瘍の2例：EMA, CD79a免疫染色の病理診断的意義 （ポスター） 2021/09/23
5件表示
全件表示(128件)
mail